208 related articles for article (PubMed ID: 18164870)
41. Optimized dose distribution of Gammamed plus vaginal cylinders.
Supe SS; Bijina TK; Varatharaj C; Shwetha B; Arunkumar T; Sathiyan S; Ganesh KM; Ravikumar M
Med Dosim; 2009; 34(1):20-5. PubMed ID: 19181251
[TBL] [Abstract][Full Text] [Related]
42. A multiple-site perineal applicator (MUPIT) for treatment of prostatic, anorectal, and gynecologic malignancies.
Martinez A; Cox RS; Edmundson GK
Int J Radiat Oncol Biol Phys; 1984 Feb; 10(2):297-305. PubMed ID: 6706724
[TBL] [Abstract][Full Text] [Related]
43. Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure.
Hsu SM; Yeh CY; Yeh TC; Hong JH; Tipton AY; Chen WL; Sun SS; Huang DY
Med Phys; 2008 Dec; 35(12):5558-64. PubMed ID: 19175113
[TBL] [Abstract][Full Text] [Related]
44. Effects of prescription depth, cylinder size, treatment length, tip space, and curved end on doses in high-dose-rate vaginal brachytherapy.
Li S; Aref I; Walker E; Movsas B
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1268-77. PubMed ID: 17336226
[TBL] [Abstract][Full Text] [Related]
45. A novel method for the evaluation of uncertainty in dose-volume histogram computation.
Henríquez FC; Castrillón SV
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1263-71. PubMed ID: 18313532
[TBL] [Abstract][Full Text] [Related]
46. [Measurement of the distance of the rectal mucosa from a gynecologic afterloading applicator based on the drop in performance of a cobalt-60-source].
Schrader R; Bahnsen J; Schrader D; Frischbier HJ
Strahlenther Onkol; 1994 Feb; 170(2):103-6. PubMed ID: 8108775
[TBL] [Abstract][Full Text] [Related]
47. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
48. High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity.
Monroe AT; Faricy PO; Jennings SB; Biggers RD; Gibbs GL; Peddada AV
Brachytherapy; 2008; 7(1):7-11. PubMed ID: 18299109
[TBL] [Abstract][Full Text] [Related]
49. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer.
Sato M; Mori T; Shirai S; Kishi K; Inagaki T; Hara I
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1002-9. PubMed ID: 18448272
[TBL] [Abstract][Full Text] [Related]
50. [Innovation in gynaecological brachytherapy: new technologies, pulse dose-rate brachytherapy, image, definition of new volumes of interest and their impact on dosimetry: application in a clinical research programme "STIC"].
Haie-Meder C; Peiffert D
Cancer Radiother; 2006 Nov; 10(6-7):402-9. PubMed ID: 16884941
[TBL] [Abstract][Full Text] [Related]
51. A quantitative three-dimensional dose attenuation analysis around Fletcher-Suit-Delclos due to stainless steel tube for high-dose-rate brachytherapy by Monte Carlo calculations.
Parsai EI; Zhang Z; Feldmeier JJ
Brachytherapy; 2009; 8(3):318-23. PubMed ID: 19217355
[TBL] [Abstract][Full Text] [Related]
52. Urethral stricture following high dose rate brachytherapy for prostate cancer.
Sullivan L; Williams SG; Tai KH; Foroudi F; Cleeve L; Duchesne GM
Radiother Oncol; 2009 May; 91(2):232-6. PubMed ID: 19097660
[TBL] [Abstract][Full Text] [Related]
53. [Proposals for common definitions of reference points in gynecological brachytherapy (author's transl)].
Chassagne D; Horiot JC
J Radiol Electrol Med Nucl; 1977 May; 58(5):371-3. PubMed ID: 886532
[TBL] [Abstract][Full Text] [Related]
54. Inverse planning simulated annealing for magnetic resonance imaging-based intracavitary high-dose-rate brachytherapy for cervical cancer.
Kubicky CD; Yeh BM; Lessard E; Joe BN; Speight JL; Pouliot J; Hsu IC
Brachytherapy; 2008; 7(3):242-7. PubMed ID: 18468959
[TBL] [Abstract][Full Text] [Related]
55. A prospective analysis of catheter complications for gynecological cancers treated with interstitial brachytherapy in the 3D era.
Mendez LC; Lang P; Patel C; D'Souza D; Gladwish A; D'Alimonte L; Taggar A; Barnes E; Barbera L; Leung E
Brachytherapy; 2019; 18(1):44-49. PubMed ID: 30316724
[TBL] [Abstract][Full Text] [Related]
56. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer.
Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook JM
Brachytherapy; 2008; 7(2):200-5. PubMed ID: 18362087
[TBL] [Abstract][Full Text] [Related]
57. EPR/alanine dosimetry in LDR brachytherapy--a feasibility study.
Schultka K; Ciesielski B; Serkies K; Sawicki T; Tarnawska Z; Jassem J
Radiat Prot Dosimetry; 2006; 120(1-4):171-5. PubMed ID: 16565206
[TBL] [Abstract][Full Text] [Related]
58. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
[TBL] [Abstract][Full Text] [Related]
59. Individual fraction optimization vs. first fraction optimization for multichannel applicator vaginal cuff high-dose-rate brachytherapy.
Symon Z; Menhel J; Alezra D; Pfeffer MR
Brachytherapy; 2006; 5(4):211-5. PubMed ID: 17118311
[TBL] [Abstract][Full Text] [Related]
60. In vivo dosimetry in gynecological applications-A feasibility study.
Van Gellekom MPR; Canters RAM; Dankers FJWM; Loopstra A; van der Steen-Banasik EM; Haverkort MAD
Brachytherapy; 2018; 17(1):146-153. PubMed ID: 28528720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
